Intellectual Property

CRISPR IP Licensing

The first patent in its kind in the world

ToolGen’s CRISPR/Cas system employs CRISPR/Cas9 in eukaryotic cell, the first patent of its kind in the world (by the earliest application date).
In addition, ToolGen’s original patent covers expansive claims on the composition and cell application of CRISPR/Cas system for the purpose of utilizing genome editing.

CRISPR IP

KOREA/CHINA/HONGKONG /JAPAN
EUROPE/CANADA/BRAZIL/INDIA
SINGAPORE/USA/AUSTRALIA

Licensing

ToolGen intends to grow together with diverse fields by licensing its CRISPR IP to them.
  • Therapeutics and Drug Discovery applications
  • Genome-edited plant and seed
  • Genome-edited animal
  • Gene-engineering Research Tools
  • Cell Lines and Animal Models Development applications
  • CROs, CMO/CDMOs applications